Updates to Prescribing Medicines in Pregnancy database, December 2022

TGA

The Prescribing Medicines in Pregnancy database has now been updated to include the following new entries:

  • asciminib hydrochloride - pregnancy category D
  • anifrolumab - pregnancy category C
  • bilastine - pregnancy category B3
  • bimekizumab - pregnancy category C
  • clobetasol - pregnancy category B3
  • difelikefalin - pregnancy category B1
  • diroximel fumarate - pregnancy category B3
  • dostarlimab - pregnancy category D
  • estetrol (as monohydrate) - pregnancy category B3
  • faricimab - pregnancy category D
  • influenza vaccine (seasonal; recombinant ) - pregnancy category B1
  • maribavir - pregnancy category D
  • mobocertinib succinate - pregnancy category D
  • osilodrostat - pregnancy category D
  • patisiran - pregnancy category D
  • pegcetacoplan - pregnancy category B3
  • pemigatinib - pregnancy category D
  • ponesimod - pregnancy category D
  • pneumococcal vaccine, polysaccharides conjugate - pregnancy category B1
  • rabies vaccine (inactivated) - pregnancy category B2
  • selumetinib - pregnancy category D
  • selinexor - pregnancy category D
  • somapacitan - pregnancy category B1
  • somatrogon - pregnancy category B1
  • sotorasib - pregnancy category B3
  • tepotinib - pregnancy category D
  • tixagevimab; cilgavimab - pregnancy category B2
  • trastuzumab deruxtecan - pregnancy category D
  • treosulfan - pregnancy category D
  • vosoritide - pregnancy category B2

The following entries have been amended:

  • COVID-19 Vaccine - ChAdOx1-S - pregnancy category from B2 to B1
  • COVID-19 Vaccine - elasomeran - change of name: COVID-19 Vaccine (mRNA)
  • COVID-19 Vaccine - tozinameran - change of name: COVID-19 Vaccine (mRNA)
  • pneumococcal vaccine, 23-valent polysaccharide or 10- or 13-valent conjugate - change of name: pneumococcal vaccine, capsular polysaccharides
  • COVID-19 Vaccine - SARS-CoV-2 rS (NVX-CoV2373) - change of name: COVID-19 Vaccine (recombinant protein)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.